ReviewFrontiers in oncology2026
Immune checkpoint inhibitors in resectable non-small cell lung cancer: recent successes and ongoing challenges.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between prognostic nutritional index and prognosis in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.Frontiers in nutrition · 2026Pooled it
- Course of Step Counts During Systemic Treatment for Non-small Cell Lung Cancer-Observational Data from a Prematurely Terminated Prospective Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic treatment for resectable early-stage non-small cell lung cancer (NSCLC) has historically consisted of chemotherapy, with limited efficacy and substantial toxicity. Immune checkpoint inhibitors (ICI) have found increasing use in neoadjuvant, adjuvant, and perioperative settings. In this review, we summarize major clinical trials using ICI in the adjuvant, neoadjuvant, and perioperative settings. We further discuss novel biomarkers, including pathologic response, ctDNA, genomic and protein expression patterns, and machine learning approaches such as radiomics and digital pathology. Finally, we discuss recent and ongoing trials of different escalation approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.